En español
NIDA

Buprenorphine

Study Points to Individualized Therapy for Opioid Addiction

Trial participants who were addicted to opioid painkillers and did not inject drugs stayed in treatment longer and achieved better outcomes than those who were addicted to heroin or injected drugs.

ED-Initiated Buprenorphine Outperforms Referral or SBIRT for ED Patients With Opioid Addiction

Emergency department visits present prime opportunities to identify people with opioid addiction and provide them with onsite initiation of treatment with buprenorphine/naloxone.

Long-Term Follow-Up of Medication-Assisted Treatment for Addiction to Pain Relievers Yields “Cause for Optimism”

In the first long-term follow-up of patients treated with buprenorphine/naloxone for addiction to opioid pain relievers, half reported that they were abstinent from the drugs 18 months after starting the therapy.

Patients Addicted to Opioid Painkillers Achieve Good Results With Outpatient Detoxification

A significant portion of individuals who are addicted to opioid painkillers may initiate and maintain abstinence with a brief but intensive outpatient detoxification treatment followed by opioid antagonist therapy using naltrexone.

Gene Variants Reduce Opioid Risks

Two recent studies suggest that genotyping may enable clinicians to base therapies on individual patients’ potential responsiveness to opioid drugs’ therapeutic effects and vulnerability to their harmful effects.

Dr. Evan D. Kharasch Joins the Institute of Medicine

Dr. Kharasch is a NIDA-funded researcher known for a broad range of research into how drugs are metabolized in the body.

Medications That Treat Opioid Addiction Do Not Impair Liver Health

A trial of buprenorphine/naloxone (Bup/Nx) showed no evidence that the medicine was associated with liver damage. The drug gave results similar to those of methadone. The study data indicate that although most patients can be treated safely with either methadone or Bup/Nx without major concern for liver injury, clinicians are advised to continue to monitor the liver health of their patients who are on methadone or Bup/Nx therapy.

Dr. Marilyn Huestis Q & A: Matching Drug Effects to Drug Concentrations

Dr. Marilyn Huestis of NIDA’s Intramural Research Program talks about conducting research on drug effects with human subjects, developing tests to help law enforcement identify drugged drivers, and an assay to help identify children whose prenatal exposure to anti-HIV drugs may put them at risk for adverse developmental outcomes.

Q & A: Dr. Redonna Chandler

The chief of NIDA's Services Research Branch talks about drug abuse treatment within the criminal justice system, and assesses the challenges facing drug abuse treatment overall in the United States.

More Convenient Preparations of Buprenorphine Pass Test

Soluble-film preparations of buprenorphine suppressed heroin abusers’ withdrawal symptoms with no serious side effects in a recent clinical trial. They dissolved more rapidly in the mouth than the pill form of the medication, providing faster relief.

Pages